C4 Therapeutics (NASDAQ:CCCC) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies that harness the body’s natural protein homeostasis pathways. The company’s proprietary “Modular Assembly of Degraders” (MAD) platform enables the design of bifunctional molecules that selectively target disease-causing proteins for degradation, rather than merely inhibiting their activity. By leveraging structure-based drug design and advanced screening technologies, C4 Therapeutics aims to expand the range of druggable targets, with an initial focus on oncology and immunology.
The company’s pipeline features multiple programs in preclinical and early clinical development across oncology and inflammation. C4 Therapeutics has advanced protein degraders directed at bromodomain-containing proteins, kinases, and transcription factors that have historically proven difficult to address with conventional small molecules. Through a strategic collaboration with Sanofi initiated in 2019, C4 Therapeutics is advancing degraders targeting key oncology pathways and exploring additional partnerships to broaden the application of its platform. The company continues to initiate discovery alliances with pharmaceutical partners to accelerate the translation of novel degradation modalities into potential therapies.
Founded in 2015 and headquartered in Cambridge, Massachusetts, C4 Therapeutics was established by a team of experts in chemical biology, medicinal chemistry, and drug discovery. The company maintains state-of-the-art research laboratories in the Greater Boston area, positioning it within one of the world’s leading biotechnology hubs. C4 Therapeutics has since grown its capabilities to include integrated discovery, translational biology, and early clinical development functions, enabling seamless progression of its therapeutic candidates from concept to human studies.
C4 Therapeutics is led by President and Chief Executive Officer Gregory T. Verdine, a pioneer in chemical biology and targeted protein degradation, alongside a management team comprising seasoned industry professionals. Under their guidance, the company is committed to advancing its innovative portfolio of degrader molecules and forging strategic collaborations to address unmet medical needs. By combining proprietary science with a disciplined development strategy, C4 Therapeutics strives to deliver transformative therapies for patients worldwide.
